Share on LinkedInShare on LinkedIn

ARTICLE · 01 JULY 2013

US Supreme Court Ruling On Patent Eligibility Of DNA

The opinion of the US Supreme Court issued on June 13th, 2013 relating to Myriad Genetics' patent of BRCA genes is breaking news and is suggested to have a major impact on gene patenting.

NetherlandsIntellectual Property

Article by Peter ten Haaft and Thea van der Wijk

Isolated unaltered natural DNA is not patent eligible; man-made DNA (such as cDNA) that is distinguishable from natural DNA, remains patent eligible.

The opinion of the US Supreme Court issued on June 13th, 2013 (http://www.supremecourt.gov/opinions/12pdf/12-398_1b7d.pdf) relating to Myriad Genetics' patent of BRCA genes is breaking news and is suggested to have a major impact on gene patenting.

Summary

The Supreme Court ruled that isolated unaltered, natural deoxyribonucleic acid (DNA) sequences are not patentable based on section 101 of the US patent act (35 U.S.C. §101), irrespective of the industrial application and inventiveness of such DNA.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from